Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) have received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) CEO Mark J. Foley sold 26,279 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $24.94, for a total transaction of $655,398.26. Following the completion of the transaction, the chief executive officer now owns 866,654 shares […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) CEO Mark J. Foley sold 31,279 shares of the firm’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $30.72, for a total transaction of $960,890.88. Following the completion of the transaction, the chief executive officer now owns 891,933 shares […]
Flaharty Asset Management LLC increased its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) by 8.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,452 shares of the biopharmaceutical company’s stock after buying an additional 1,000 shares during the period. Flaharty Asset […]
Revance Therapeutics, Inc. today announced that the company will be participating in the following investor conferences.
William Blair 43rd Annual Growth Stock Conference
Chief Executive Officer. | May 23, 2023